Dan V. Mihailescu

Dan V. Mihailescu

Auto-generated profile, based on publicly available information

Dan V. Mihailescu

Division of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
PMPamela Martyn-Nemeth
Pamela Martyn-Nemeth
SFSarah Schwarz Farabi
Sarah Schwarz Farabi
DMDan Mihailescu
Dan Mihailescu
JNJeffrey Nemeth
Jeffrey Nemeth
LQLauretta Quinn
Lauretta Quinn

23 October 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
BGBen S Gerber
Ben S Gerber
LRLauren Rapacki
Lauren Rapacki
ACAmparo Castillo
Amparo Castillo
JTJessica Tilton
Jessica Tilton
DTDaniel R Touchette
Daniel R Touchette
LSLisa K Sharp
Lisa K Sharp
Given the increasing prevalence of diabetes and the lack of patients reaching recommended therapeutic goals, novel models of team-based care are emerging. These teams typically include a combination of physicians, nurses, case managers, pharmacists, and community-based peer health promoters (HPs). Recent evidence supports the role of pharmacists in diabetes management to improve glycemic control, as they offer expertise in medication management with the ability to collaboratively intensify therapy. However, few studies of pharmacy-based models of care have focused on low income, minority populations that are most in need of intervention. Alternatively, HP interventions have focused largely upon low income minority groups, addressing their unique psychosocial and environmental challenges in diabetes self-care. This study will evaluate the impact of HPs as a complement to pharmacist management in a randomized controlled trial.

1 April 2018 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
JSJoseph M Shulan
Joseph M Shulan
LVLeonid Vydro
Leonid Vydro
ASArthur B Schneider
Arthur B Schneider
DMDan V Mihailescu
Dan V Mihailescu
With increasing numbers of childhood cancer survivors who were treated with radiation, there is a need to evaluate potential biomarkers that could signal an increased risk of developing thyroid cancer. We aimed to examine the relationships between thyrotropin and thyroglobulin levels and the risk of developing thyroid nodules and cancer in a cohort of radiation-exposed children. 764 subjects who were irradiated in the neck area as children were examined and followed for up to 25 years. All subjects underwent a clinical examination, measurements of thyrotropin, thyroglobulin levels and thyroid imaging. At baseline, 216 subjects had thyroid nodules and 548 did not. Of those with nodules, 176 underwent surgery with 55 confirmed thyroid cancers. During the follow-up, 147 subjects developed thyroid nodules including 22 with thyroid cancer. Thyroglobulin levels were higher in subjects with prevalent thyroid nodules (26.1 ng/mL vs 9.37 ng/mL; P < 0.001) and in those who had an initial normal examination but later developed thyroid nodules (11.2 ng/mL vs 8.87 ng/mL; P = 0.017). There was no relationship between baseline thyrotropin levels and the prevalent presence or absence of thyroid nodules, whether a prevalent neoplasm was benign or malignant, subsequent development of thyroid nodules during follow-up or whether an incident nodule was benign or malignant. In conclusion, in radiation-exposed children, higher thyroglobulin levels indicated an increased risk of developing thyroid nodules but did not differentiate between benign and malignant neoplasms. There was no association between the baseline TSH level and the risk of developing thyroid nodules or cancer.

23 November 2010 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
DMDan V. Mihailescu
Dan V. Mihailescu
AVAvni Vora
Avni Vora
TMTheodore Mazzone
Theodore Mazzone

1 March 2020 in Thyroid®
Verified
Journal Article
Closed access
LVLeonid Vydro
Leonid Vydro
CKCari M. Kitahara
Cari M. Kitahara
JLJay H. Lubin
Jay H. Lubin
ASArthur B. Schneider
Arthur B. Schneider
DMDan V. Mihailescu
Dan V. Mihailescu
Background: Whether radiation-induced thyroid cancer affects survival rates has not been clearly elucidated. Survival could be affected by the thyroid cancer itself, its treatment, or by being a sign of susceptibility to other cancers. The objective of the current study was to determine if the development of thyroid cancer is associated with a differential survival in radiation-exposed individuals. Methods: We conducted a matched prospective cohort mortality follow-up study based on data from a cohort of 4296 individuals who were irradiated predominantly for enlarged tonsils during their childhood (between 1939 and 1962) and were prospectively followed since 1974. The study matched an irradiated subject who developed (was exposed to) thyroid cancer (a “case”) and two irradiated subjects, who had not developed (were not exposed to) thyroid cancer (“controls”) by the time of case incidence. The two controls were randomly matched to cases by sex, year of birth, age at radiation treatment, and radiation dose. Then, using a stratified Cox analysis, we compared survival time from the date of thyroid cancer diagnosis or time of selection to either date of death or the end of the observation period (December 31, 2016). Vital status and causes of death were determined using the National Death Index (1979–2016), the Social Security Death Index (1974–1979), and study files. Cause of death was categorized as cardiovascular, malignancy, or other. Results: A total of 1008 subjects were included in the analysis, including 353 thyroid cancer cases. At the end of the study period, 162 of 655 (24.7%) of individuals without thyroid cancer had died compared with 100 of 353 (28.3%) of the subjects with thyroid cancer. The hazard ratio (HR) for all-cause mortality, comparing the thyroid cancer cases to controls, was close to unity (HR = 1.01 [0.77–1.33]). HRs remained insignificant after eliminating matched sets with microcarcinomas, defined as tumor size <10 mm (HR = 1.39 [0.96–2.03]). Distribution of the causes of death taking into account age and the time of observation differed between cases and controls (p < 0.05). Neither increased cardiovascular-related nor malignancy-related mortality was associated with radiation-induced thyroid cancer. Conclusions: Among individuals irradiated for benign conditions in childhood, development of thyroid cancer was not associated with decreased all-cause survival.